Antibody Response to Symptomatic Infection With SARS‐CoV‐2 Omicron Variant Viruses, December 2021–June 2022 is a research paper published in Influenza and Other Respiratory Viruses (2024). On theSindex it has a DataRank of 0. It has been cited 1 time.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Centers for Disease Control and Prevention
Grant: 75D30121C11513
Centers for Disease Control and Prevention
Grant: 75D30121C11519
Centers for Disease Control and Prevention
Grant: 75D30121C11529
Centers for Disease Control and Prevention
Grant: 75D30121C11909
Centers for Disease Control and Prevention
Grant: 75D30121C12246
Centers for Disease Control and Prevention
Grant: 75D30121C12279
Centers for Disease Control and Prevention
Grant: 75D30121C12339
National Institutes of Health
Grant: UL1TR001857
National Institutes of Health
Grant: 5UL1TR002243-05
Vanderbilt Institute for Clinical and Translational Research (VICTR)
National Institutes of Health
Grant: 3UL1TR001857-07S1
University of Pittsburgh Clinical and Translational Science Institute
National Institutes of Health
Grant: 5UL1TR002243-03
Vanderbilt Institute for Clinical and Translational Research (VICTR)
FWCI
0.31
Citation Percentile
0.6%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals